Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril
Key Points
Key points are not available for this paper at this time.
Abstract
clinicaltrials.gov Identifier: NCT01035255.
Like
Bookmark
Share
Like
Bookmark
Share
Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril | Synapse